Our research program is focused on antibodies for equine use. We believe that an antibody is useful to the immune system at any and all times. Vaccination programs are important and are your first line of defense . . . but even vaccinated animals become ill. Mg Biologics has been researching the benefit of plasma designed to support your horse during these highly stressful situations. Our theory is IV transfusion is beneficial and efficacious both after the exposure to a challenge and after the onset of symptoms. Antibodies, we believe, have the ability to reduce the duration of a disease, to reduce the severity of the disease or even to arrest the disease entirely.

Rhodococcus equi: ReSolution Rhodococcus Equi Antibody is now available as a USDA licensed product. Our Rhodococcus equi Antibody titers regularly test at 1:10,000 specific to Vap A. ReSolution Rhodococcus Equi Antibody is made from three strains of R. equi and is the only licensed R. equi antibody that has published data in controlled challenge studies demonstrating to be efficacious as an aid in the control of Rhodococcus equi. A PDF of the study, published in Veterinary Therapeutics can be viewed here.

Salmonella: We are working with a Salmonella Re mutant which is a Salmonella antibody as well as an anti-endotoxin. Initial research has shown benefits against gram negative organisms causing diarrhea and septicimia.

E. coli J-5: The E. coli strain we are studying is an anti-endotoxin. An efficacy trial has been set to evaluate the effectiveness of anti-lipopolysaccharide hyper immune plasma as an aid in the control of Escherichia coli.

Clostridium perfringens A: We are researching the application of Clostridium perfringens A. Veterinarians have expressed a need for this specific antibody with antitoxins against Beta and enterotoxins, and as such, we hope to begin working with the USDA for efficacy testing.

Clostridium difficile: Our research is centered around a strain that has the A and B toxins. This product is being researched for use as an IV administration of antitoxins A and B in foal diarrhea situations. This product has also been researched in neonatal swine and has shown increased weight gain in piglets challenged with the disease when compared with controls.

Streptococcus equi: We are the first and only company with a Streptococcus Equi Antibody licensed by the USDA (conditionally licensed). Research has shown the administration of Streptococcus equi antibodies can reduce the mortality, duration, and severity of the disease after the clinical signs of disease have been observed. Research is ongoing and we have finished a second trial evaluating the efficacy of plasma with S. equi antibodies when challenged with an S. equi organism.

Rotavirus: Our rotavirus titers have been tested at Purdue University and are as high as 1:16,000. A typical protective immune response is 1:64. Research will be focused on efficacy at low dosage levels.

Streptococcus zooepidemicus: Research is ongoing.

Clostridium botulinum B: Research is ongoing.